Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis

Cancer Research

Volumn 71, Issue 10, 2011, Pages 3616-3624

  Craig, Vanessa J ^a   Cogliatti, Sergio B ^b   Rehrauer, Hubert ^a   Wündisch, Thomas ^c   Müller, Anne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; MICRORNA; MICRORNA 203; UNCLASSIFIED DRUG;

ABL1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GASTRIC MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; GENETIC REGULATION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LENTIVIRINAE; LYMPHOMA CELL LINE; MOUSE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTO ONCOGENE; STOMACH CARCINOGENESIS; TUMOR BIOPSY;

ANIMALS; BIOPSY; CELL LINE, TUMOR; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MICE; MICE, INBRED BALB C; MICRORNAS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS V-ABL; PIPERAZINES; PYRIMIDINES; STOMACH NEOPLASMS;

EID: 79956083983     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3907     Document Type: Article

References (39)

1. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005: 307-13.
2. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53. (Pubitemid 39025059)
3. Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002;99:2541-4. (Pubitemid 34525443)
4. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415-20. (Pubitemid 46218852)
5. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7. (Pubitemid 23259233)
6. Wundisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-24. (Pubitemid 46657403)
7. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wündisch T, Neubauer A, et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010;115:581-91.
8. Craig VJ, Cogliatti SB, Arnold I, Gerke C, Balandat JE, Wündisch T, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010;24:1186-96.
9. Knorr C, Amrehn C, Seeberger H, Rosenwald A, Stilgenbauer S, Ott G, et al. Expression of costimulatory molecules in low-grade mucosa-associated lymphoid tissue-type lymphomas in vivo. Am J Pathol 1999;155:2019-27.
10. Mueller A, O'Rourke J, Chu P, Chu A, Dixon MF, Bouley DM, et al. The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Am J Pathol 2005;167:797-812. (Pubitemid 41216363)
11. Enno A, O'Rourke J, Braye S, Howlett R, Lee A. Antigen-dependent progression of mucosa-associated lymphoid tissue (MALT)-type lymphoma in the stomach. Effects of antimicrobial therapy on gastric MALT lymphoma in mice. Am J Pathol 1998;152:1625-32. (Pubitemid 28275020)
12. Enno A, O'Rourke JL, Howlett CR, Jack A, Dixon MF, Lee A. MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma. Am J Pathol 1995;147:217-22.
13. Mueller A, O'Rourke J, Grimm J, Guillemin K, Dixon MF, Lee A, et al. Distinct gene expression profiles characterize the histopathological stages of disease in Helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Proc Natl Acad Sci U S A 2003;100:1292-7. (Pubitemid 36183995)
14. Huynh MQ, Wacker HH, Wundisch T, Sohlbach K, Kim TD, Krause M, et al. Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas. Leuk Lymphoma 2008;49:974-83. (Pubitemid 351942753)
15. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-7. (Pubitemid 38083007)
16. Ambros V. The functions of animal microRNAs. Nature 2004;431: 350-5. (Pubitemid 39265675)
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801. (Pubitemid 41549891)
19. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. (Pubitemid 43357945)
20. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. (Pubitemid 38327724)
21. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. (Pubitemid 40343076)
22. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435: 839-43. (Pubitemid 40839736)
23. Bertrand S, Berger R, Philip T, Bernheim A, Bryon PA, Bertoglio J, et al. Variant translocation in a nonendemic case of Burkitt's lymphoma: t (8;22) in an Epstein-Barr virus negative tumour and in a derived cell line. Eur J Cancer 1981;17:577-84. (Pubitemid 11104278)
24. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10. (Pubitemid 34679544)
25. Sun B, Jiang G, Zaydan MA, La Russa VF, Safah H, Ehrlich M. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors. Cancer Res 2001;61:6931-7. (Pubitemid 32896521)
26. Alvarez AR, Sandoval PC, Leal NR, Castro PU, Kosik KS. Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiol Dis 2004;17:326-36. (Pubitemid 39345788)
27. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, et al. Genetic and epigenetic silencing of micro-RNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008;13:496-506. (Pubitemid 351763902)
28. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
29. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M, et al. MicroRNA signatures in Helicobacter pyloriinfected gastric mucosa. Int J Cancer 2011;128:361-70.
30. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2009.
31. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955-63.
32. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-68. (Pubitemid 46548930)
33. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33:1290-7. (Pubitemid 41439922)
34. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G, et al. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ 2008;15:1187-95.
35. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:118-22.
36. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991;65:1165-75. (Pubitemid 121001330)
37. Zipfel PA, Grove M, Blackburn K, Fujimoto M, Tedder TF, Pendergast AM. The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. J Immunol 2000;165:6872-9. (Pubitemid 32001156)
38. Lin K, Glenn MA, Harris RJ, Duckworth AD, Dennett S, Cawley JC, et al. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. Cancer Res 2006;66:7801-9.
39. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8. (Pubitemid 43801135)